Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast AS's quarterly cash, cash equivalents, marketable securities
declined
from Dec. 2025 ($176.38 Mil) to Mar. 2026 ($165.04 Mil) but then
stayed the same
from Mar. 2026 ($165.04 Mil) to Jun. 2026 ($125.88 Mil).
Coloplast AS's annual cash, cash equivalents, marketable securities
declined
from Sep. 2023 ($130.37 Mil) to Sep. 2024 ($117.30 Mil) but then
increased
from Sep. 2024 ($117.30 Mil) to Sep. 2025 ($148.92 Mil).
Coloplast AS (OTCPK:CLPBY) Cash, Cash Equivalents, Marketable Securities Explanation
Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Coloplast AS Cash, Cash Equivalents, Marketable Securities Related Terms
Coloplast AS Cash, Cash Equivalents, Marketable Securities Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Cash, Cash Equivalents, Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS Cash, Cash Equivalents, Marketable Securities Chart
Coloplast AS Cash, Cash Equivalents, Marketable Securities Calculation
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.
What does a Cash, Cash Equivalents, Marketable Securities of $126 Mil mean?
Coloplast AS (CLPBY) has a Cash, Cash Equivalents, Marketable Securities of $126 Mil as of Jun. 2026. The total cash, cash equivalents and marketable securities a company has on hand. View historical data on Coloplast AS and its competitors.
Is Coloplast AS's Cash, Cash Equivalents, Marketable Securities too high?
Coloplast AS's current Cash, Cash Equivalents, Marketable Securities is $126 Mil. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Cash, Cash Equivalents, Marketable Securities compare to ISRG and BDX?
Coloplast AS's Cash, Cash Equivalents, Marketable Securities of $126 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash, Cash Equivalents, Marketable Securities for a Medical Devices & Instruments company?
A good Cash, Cash Equivalents, Marketable Securities depends on the Medical Devices & Instruments industry context. However, Cash, Cash Equivalents, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash, Cash Equivalents, Marketable Securities mean?
A high Cash, Cash Equivalents, Marketable Securities can signal that a stock is expensive relative to its fundamentals. The total cash, cash equivalents and marketable securities a company has on hand. View historical data on Coloplast AS and its competitors. Coloplast AS's current Cash, Cash Equivalents, Marketable Securities is $126 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.17, compared to a current price of $6.98 — trading 42.6% below its estimated fair value. The current Cash, Cash Equivalents, Marketable Securities is $126 Mil. Coloplast AS's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash, Cash Equivalents, Marketable Securities calculated?
Cash, Cash Equivalents, Marketable Securities is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Cash, Cash Equivalents, Marketable Securities is $126 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.98 is trading 42.6% below its estimated GF Value™ of $12.17.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
Cash, Cash Equivalents, Marketable Securities: $126 Mil
GF Value™: $12.17 vs. price of $6.98 (42.6% below fair value)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBY
Cash, Cash Equivalents, Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
